Research Topics
| D A AhlquistSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Molecular detection of colorectal neoplasiaDavid A Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Gastroenterology 138:2127-39. 2010..This review addresses the biological rationale, technical advances, recent clinical performance data, and remaining issues with molecular screening for colorectal cancer...
The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasiaDavid A Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Gastroenterol Hepatol 10:272-7.e1. 2012..We compared the sensitivities of a multimarker test for stool DNA (sDNA) and a plasma test for methylated septin 9 (SEPT9) in identifying patients with large adenomas or CRC...
Next-generation stool DNA test accurately detects colorectal cancer and large adenomasDavid A Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Gastroenterology 142:248-56; quiz e25-6. 2012..We assessed colorectal neoplasm detection by a next-generation sDNA test and effects of covariates on test performance...
Stool DNA and occult blood testing for screen detection of colorectal neoplasiaDavid A Ahlquist
Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Intern Med 149:441-50, W81. 2008..Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting...
Stool screening for colorectal cancer: evolution from occult blood to molecular markersDavid A Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Clin Chim Acta 315:157-68. 2002..Participation rates for colorectal cancer screening remain low due, in part, to perceived discomfort, potential harm, and high costs with available tools...
Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panelD A Ahlquist
Division of Gastroenterology and Hepatology, Department of Biostatistics, and Division of Molecular Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
Gastroenterology 119:1219-27. 2000..We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without...
Optimization of CT colonography technique: prospective trial in 180 patientsJ G Fletcher
Department of Diagnostic Radiology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Radiology 216:704-11. 2000..To assess the added benefits of prone positioning in addition to supine positioning and oral iodinated contrast medium for help in the detection of colonic polyps at computed tomographic (CT) colonography...
Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in womenL A Boardman
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Medicine (Baltimore) 79:293-8. 2000..In particular, the relative risk for cancer in females with IMMP was significantly increased, as is true in females with PJS. However, LKB1 mutations did not contribute to the development of IMMP in the patients tested...
Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivativeR S Wooten
Department of Medicine, Mayo Clinic, Rochester, MN 55905
Lasers Surg Med 8:294-300. 1988..Other HpD-related complications included skin hyperpigmentation, ocular discomfort, pruritus, pain at injection site, and urticaria. CP and the restrictive measures to avoid it represent major disadvantages of the clinical use of HpD...
CT colonography without cathartic preparation: feasibility studyM R Callstrom
Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Radiology 219:693-8. 2001..Sensitivity for polyp detection in patients with adequate stool labeling approaches the sensitivity for polyp detection in prepared colons...
A search for germline APC mutations in early onset colorectal cancer or familial colorectal cancer with normal DNA mismatch repairL A Boardman
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Genes Chromosomes Cancer 30:181-6. 2001..All appeared to be polymorphisms present in similar proportions in an average-risk population. We conclude that germline APC mutations do not account for familial MSS (stable microsatellite) CRC associated with few synchronous polyps...
Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosisP S Kamath
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Gastroenterology 118:905-11. 2000..The response of gastric mucosal lesions in cirrhotic patients with portal hypertension, namely, portal hypertensive gastropathy (PHG) and gastric vascular ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known...
Localization of hematoporphyrin. Derivative to human colorectal cancerR S Wooten
Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota 55905
Cancer 64:1569-76. 1989..6 microgram/g versus 0.1 microgram/g, P less than 0.001). The authors conclude that HpD preferentially localizes to human colorectal cancer and this is relevant to the photodetection and phototherapy of colorectal neoplasia...
Colorectal cancer prevention and detection. IntroductionDavid A Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Gastroenterol Clin North Am 31:xi-xii. 2002
A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screeningHongzhi Zou
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 15:1115-9. 2006..This study shows that not all CRCs are associated with increased fecal levels of long DNA. Long DNA degrades with fecal storage, and measures to stabilize this analyte must be considered for optimal use of this marker...
A novel method to capture methylated human DNA from stool: implications for colorectal cancer screeningHongzhi Zou
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Clin Chem 53:1646-51. 2007..Assay of methylated DNA markers in stool is a promising approach for colorectal cancer (CRC) screening. A method to capture hypermethylated CpG islands from stool would enrich target analyte and allow optimal assay sensitivity...
Highly methylated genes in colorectal neoplasia: implications for screeningHongzhi Zou
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 16:2686-96. 2007..Comethylation of these genes is common, and pursuit of complementary markers for methylation-negative neoplasms is a rational strategy to optimize screening sensitivity...
Stool screening for colorectal cancer: molecular approachesNeal K Osborn
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Gastroenterology 128:192-206. 2005..Further marker discovery and technologic refinements should translate into improved test performance and fuel a continued evolution with this screening approach...
Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polypsC Daniel Johnson
Department of Radiology, Mayo Clinic Rochester, MN 55905, USA
Clin Gastroenterol Hepatol 2:314-21. 2004..01]). CONCLUSIONS: Double-read CT colonography is significantly more sensitive in detecting polyps than single-read double contrast barium enema. DCBE was significantly more specific than CT colonography...
Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasiaPaul J Limburg
Division of Gastroenterology and Hepatology and Department of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Gastroenterol 98:2299-305. 2003..Further investigation of tumor-derived, rather than blood-based, biomarkers may be a more rewarding approach to stool screening for colorectal neoplasia...
Stool-based DNA tests for colorectal cancer: clinical potential and early resultsDavid A Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
Rev Gastroenterol Disord 2:S20-6. 2002..Large, multicenter, comparative studies addressing the performance of stool-based DNA testing in the general population will soon be completed and will promise to validate the readiness of this approach for widespread application...
DNA integrity as a potential marker for stool-based detection of colorectal cancerKevin A Boynton
Applied Research Group, EXACT Sciences Corporation, 63 Great Road, Maynard, MA 01754, USA
Clin Chem 49:1058-65. 2003..An assay of fecal DNA integrity may be a useful biomarker for the detection of CRC...
Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferencesThomas M Gluecker
Department of Radiology, Mayo Clinic Rochester, 200 First Street SW, MN 55905, USA
Radiology 227:378-84. 2003..0% vs 0.4%; P <.001). CONCLUSION: Patients undergoing colorectal cancer screening prefer CT colonography to both colonoscopy and DCBE. The majority of patients experience discomfort and inconvenience with cathartic bowel preparation...
Contrast-enhanced CT colonography in recurrent colorectal carcinoma: feasibility of simultaneous evaluation for metastatic disease, local recurrence, and metachronous neoplasia in colorectal carcinomaJ G Fletcher
Department of Radiology, Mayo Clinic, East-2B, 200 First St, S.W, Rochester, MN 55905, USA
AJR Am J Roentgenol 178:283-90. 2002..The technique can also serve as a useful adjunct to colonoscopy by detecting local recurrences or metachronous disease that are endoscopically obscure or by serving as a full structural colonic examination when endoscopy is incomplete...
Second primary colorectal cancer: the consequence of management failure at several potential levelsPaul J Limburg
Ann Intern Med 136:335-7. 2002
Detection of occult upper gastrointestinal tract bleeding: performance differences in fecal occult blood testsGavin C Harewood
Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:23-8. 2002..003). CONCLUSION: The HQT test detects occult upper GI tract blood loss significantly more frequently than the HO or HS test...
Detection of colorectal disease by stool defensin assay: an exploratory studyHongzhi Zou
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Gastroenterol Hepatol 5:865-8. 2007..We evaluated the neoplasm specificity of HPN1-3 and their discriminant value as stool markers for CRC...
Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort studyPaul J Limburg
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Am J Gastroenterol 101:1872-9. 2006....
Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasiaNeal K Osborn
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Clin Gastroenterol Hepatol 4:212-8. 2006..005). CONCLUSIONS: The EYA4 gene promoter is hypermethylated commonly in sporadic and colitic neoplasia and may be associated with gene silencing. EYA4 methylation represents a candidate marker for CUC surveillance...
Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagusHongzhi Zou
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
Int J Cancer 116:584-91. 2005..Aberrant promoter methylation appears to functionally silence SFRP gene expression in esophageal adenocarcinoma...
Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinomaHongzhi Zou
Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 14:830-4. 2005....
Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based studyAmit K Gupta
Division of General Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Clin Gastroenterol Hepatol 3:150-8. 2005..However, the incidence of right-sided cancer remains unaltered and might be less affected by historically used screening interventions. Most CRCs still present symptomatically, and more effective population screening is needed...
Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening populationThomas M Gluecker
Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
Gastroenterology 124:911-6. 2003..Although such incidental findings add benefit to the screening intervention, moderate incremental costs are incurred based on additional radiologic procedures generated during short-term follow-up...
Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polypsC Daniel Johnson
Department of Radiology, Mayo Clinic Rochester, 200 First Street S.W, Rochester, Minnesota 55905, USA
Gastroenterology 125:311-9. 2003..Specificity, based on large numbers, is high and exhibits excellent agreement among observers...
Research Grants
- Colorectal Cancer Screening: Fecal Blood vs DNADavid Ahlquist; Fiscal Year: 2004..If the DNA-based test proves to have greater screening accuracy than fecal blood testing, this could translate into more effective cancer control and more efficient use of our limited health care resources. ..
